[go: up one dir, main page]

GB202006093D0 - Composition - Google Patents

Composition

Info

Publication number
GB202006093D0
GB202006093D0 GBGB2006093.5A GB202006093A GB202006093D0 GB 202006093 D0 GB202006093 D0 GB 202006093D0 GB 202006093 A GB202006093 A GB 202006093A GB 202006093 D0 GB202006093 D0 GB 202006093D0
Authority
GB
United Kingdom
Prior art keywords
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2006093.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB2006093.5A priority Critical patent/GB202006093D0/en
Publication of GB202006093D0 publication Critical patent/GB202006093D0/en
Priority to AU2021260852A priority patent/AU2021260852A1/en
Priority to PCT/EP2021/060749 priority patent/WO2021214329A1/en
Priority to CA3176300A priority patent/CA3176300A1/en
Priority to MX2022013400A priority patent/MX2022013400A/en
Priority to US17/919,589 priority patent/US20230151090A1/en
Priority to KR1020227038538A priority patent/KR20230006824A/en
Priority to JP2022564560A priority patent/JP2023523264A/en
Priority to EP21721081.4A priority patent/EP4139356A1/en
Priority to CN202180044702.8A priority patent/CN115916829A/en
Priority to BR112022021499A priority patent/BR112022021499A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB2006093.5A 2020-04-24 2020-04-24 Composition Ceased GB202006093D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB2006093.5A GB202006093D0 (en) 2020-04-24 2020-04-24 Composition
BR112022021499A BR112022021499A2 (en) 2020-04-24 2021-04-23 COMPOSITION COMPRISING AN IGE ANTIBODY
MX2022013400A MX2022013400A (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody.
PCT/EP2021/060749 WO2021214329A1 (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody
CA3176300A CA3176300A1 (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody
AU2021260852A AU2021260852A1 (en) 2020-04-24 2021-04-23 Composition comprising an IgE antibody
US17/919,589 US20230151090A1 (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody
KR1020227038538A KR20230006824A (en) 2020-04-24 2021-04-23 Compositions comprising IGE antibodies
JP2022564560A JP2023523264A (en) 2020-04-24 2021-04-23 Compositions containing IgE antibodies
EP21721081.4A EP4139356A1 (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody
CN202180044702.8A CN115916829A (en) 2020-04-24 2021-04-23 Compositions comprising IGE antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2006093.5A GB202006093D0 (en) 2020-04-24 2020-04-24 Composition

Publications (1)

Publication Number Publication Date
GB202006093D0 true GB202006093D0 (en) 2020-06-10

Family

ID=71080097

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2006093.5A Ceased GB202006093D0 (en) 2020-04-24 2020-04-24 Composition

Country Status (2)

Country Link
GB (1) GB202006093D0 (en)
WO (1) WO2021214329A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240001136A (en) * 2021-04-23 2024-01-03 킹스칼리지런던 Compositions Comprising IgE Antibodies
EP4166569A1 (en) * 2021-10-18 2023-04-19 Fondazione IRCCS Istituto Nazionale dei Tumori Antibodies directed against alpha-folate receptor
WO2025153527A1 (en) * 2024-01-19 2025-07-24 Englmeier Ludwig Diagnostic use of immunoglobulin e

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US9783613B2 (en) 2011-10-04 2017-10-10 Igem Therapeutics Limited IgE anti-HMW-MAA antibody
TWI694836B (en) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 Antibody formulation

Also Published As

Publication number Publication date
WO2021214329A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EP4256011C0 (en) Composition
GB202005911D0 (en) Composition
GB202004460D0 (en) Herbical composition
GB202018029D0 (en) Composition
GB202007377D0 (en) Composition
GB202105455D0 (en) Composition
GB202103439D0 (en) Composition
GB202016236D0 (en) Composition
GB202012895D0 (en) Composition
GB202006093D0 (en) Composition
GB202103434D0 (en) Composition
GB202000619D0 (en) Composition
EP4330363C0 (en) Composition
EP4259762C0 (en) Composition
GB202111898D0 (en) Composition
GB202104498D0 (en) Composition
GB202014635D0 (en) Composition
GB2592952B (en) Composition
GB202110358D0 (en) Composition
GB202109550D0 (en) Composition
EP4176034C0 (en) Composition
GB202108511D0 (en) Composition
GB202107377D0 (en) Composition
GB202107382D0 (en) Composition
GB202105744D0 (en) Composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)